Baloxavir marboxil an oral influenza cap-dependent endonuclease inhibitor that disables flu viruses by interfering with viral messenger RNA transcription.
It rapidly reduces influenza virus titers, and stops shedding of infectious virus faster than oseltamir.
Antiviral treatment of influenza is recommended as soon as possible for hospitalized patients and for outpatients who have increased risk for influenza related complications.
Upper respiratory tract virus levels are significantly lower with baloxavir then with oselamivir or placebo as early as 24 hours after treatment.
Baloxavir marboxil, an oral antiviral medication approved for the early treatment (within 48 hours after symptom onset), of uncomplicated influenza, and for post exposure prophylaxis against influenza in persons, five years of age and older.
Has efficacy in reducing the risks of some influenza related complications as compared with placebo.
FDA expanded the approved indication for Baloxavir marboxil use to include post-exposure prevention of influenza for patients aged 12 years and older, after contact with an individual who has the flu.
It has substantial efficacy of post exposure prophylaxis with neuaminidase inhibitors oseltimivir or zanamivir.
The therapy previously available only in tablet form, is also now available as granules for mixing in water.
Indication expanded for patients aged 12 years and older who are at high risk for developing influenza-associated complications.
Treatment with a single oral dose of baloxavir leads to a lower incidence of transmission of influenza virus to close contacts than placebo.
Randomized control trials of early treatment with baloxavir as compared with Oseltamivir or placebo showed the efficacy of a single dose of baloxavir was similar to that of. Oseltamivir or placebo taken twice daily for five days for reducing the time to alleviation of influenza symptoms in adults and adolescents. including those and increased risk for influenza related complications.
The most common adverse effects: diarrhea, bronchitis, nausea, sinusitis and headache.
Baloxavir marboxil should be avoided with dairy products, calcium-fortified beverages, or laxatives, antacids, or oral supplements containing calcium, iron, magnesium, selenium, aluminum or zinc.
Indicated for patients aged 12 years or older who had symptoms of influenza for no longer than 48 hours.
Anti-viral medication taken in that time frame can minimize symptoms and shorten the duration of the illness.
Has activity against influenza A and B strains.
Takes about 54 hours for symptoms to resolve.
Common adverse events include diarrhea, bronchitis, sinusitis and headache.